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Purpose: To investigate the effects of norrin, a nonconventional ligand for Wingless-Int (Wnt)-beta-catenin signaling
pathway, on protease-mediated death of transformed rat retinal ganglion cells (RGC-5).
Methods: Transformed RGC-5 cells were treated with 2.0 μM staurosporine (SS), a broad-spectrum protein kinase-C
inhibitor, to induce growth arrest, differentiation, and elevated levels of tissue plasminogen activator (tPA) and urokinase
plasminogen activator (uPA). RGC-5 cells were also treated with 2.0 μM SS and varying doses of recombinant norrin
(3.125 to 100 ng/ml). Activation of Wnt pathway was assessed by nuclear translocation of beta-catenin. Proteolytic activity
of tPA and uPA was determined by zymography assays and cell viability was determined by 3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyltetrazolium bromide (MTT) assays. Expression and phosphorylation of the low-density lipoprotein-
related receptor-1 (LRP-1), a cell surface receptor for tPA and uPA, was determined by immunoprecipitation and western
blot analysis.
Results: Compared to RGC-5 cells left untreated, cells treated with either SS alone or SS and norrin secreted elevated
levels of tPA and uPA. A significant number of RGC-5 cells treated with only SS underwent cell death, whereas cells
treated with SS and norrin did not, even though RGC-5 cells secreted elevated levels of tPA and uPA under both treatment
conditions. Although norrin activated the Wnt pathway, Dickkopf related protein 1 (Dkk1), an inhibitor of Wnt/beta-
catenin pathway, failed to completely block norrin’s neuroprotective effects. Assays for expression and phosphorylation
of LRP-1 indicated that tPA and uPA cause RGC-5 cell death, in part, by reducing phosphorylation of LRP-1, whereas
norrin attenuated tPA and uPA-mediated RGC cell death, in part, by restoring phosphorylation of LRP-1.
Conclusions: Our results suggest that norrin attenuates tPA- and uPA-mediated death of RGC-5 cells by activating Wnt/
beta-catenin pathway and by regulating phosphorylation of LRP-1.
Norrie disease, a severe and X-linked congenital retinal
disorder,  is  characterized  by  aberrant  vascularization,
subretinal exudation, and retinal detachment [1]. The Norrie
gene encodes a small, secreted, and cysteine-rich protein,
termed norrin or Norrie disease protein (NDP) [2]. Mice that
lack norrin have abnormal blood vessel growth in the vitreous
and a disorganized retina [3]. In addition, mice with targeted
disruption of NDP develop blindness due to lack of deep
retinal capillaries, persistent hyaloid vessels, and growth of
abnormal blood vessels in the vitreous [4,5]. Interestingly,
transgenic expression of ectopic norrin in norrin-deficient
Ndpy/- mice not only restores normal retinal vasculature, but
also  attenuates  progressive  loss  of  retinal  ganglion  cells
(RGCs) [6]. Nonetheless, the mechanisms by which norrin
attenuates loss of RGCs are unclear.
Recent studies have suggested that norrin acts as a ligand
for Wingless–Int (Wnt) receptor-beta-catenin signal pathway,
although norrin does not have sequence homology for the Wnt
family of proteins [3]. Wnts, a family of approximately 20
secreted  glycoproteins,  initiate  intracellular  signal
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transduction by binding simultaneously to two cell surface
receptors: a Frizzled (Fzd) receptor and a member of the low-
density  lipoprotein  receptor-related  protein  (LRP)  family,
LRP-5 or LRP-6 [7,8]. The Frizzled receptors, seven-pass
transmembrane receptors containing a cysteine-rich domain
(CRD), act as binding site for Wnts, while the LRP-5 and
LRP-6, single-pass transmembrane receptors, interact with
both Fzd and Wnt [8]. An important difference between norrin
and  Wnts  is  that  norrin  activates  Wnt/beta-catenin  signal
transduction  pathway  by  specifically  interacting  with
Frizzled-4 receptors, while Wnts can bind to multiple Frizzled
receptors. The central player in Wnt pathways is a cytoplasmic
protein,  the  beta-catenin,  whose  stability  initiates  the
transcription of Wnt-target genes. When a Wnt is not bound
to  Fzd  and  LRP  receptors,  glycogen  synthase  kinase-3
(GSK-3)  phosphorylates  beta-catenin  and  targets  it  to
degradation in the proteosomes. In contrast, Wnt binding to
Fzd  and  LRP  receptors  inhibits  activity  of  GSK-3;
consequently, nonphosphorylated beta-catenin translocates to
the nucleus where it forms complexes with members of T cell
factor/lymphoid enhancer factor (TCE/LEF) members, and
initiates the transcription of Wnt-target genes [8].
We have previously reported that elevated levels of two
plasminogen  activators,  urokinase  plasminogen  activator
Molecular Vision 2009; 15:26-37 <http://www.molvis.org/molvis/v15/a3>
Received 12 August 2008 | Accepted 26 December 2008 | Published 12 January 2009
© 2009 Molecular Vision
26(uPA) and tissue plasminogen activator (tPA), promote death
of RGCs in vivo [9] and death of transformed retinal ganglion
cells (RGC-5 cells) in vitro [10,11]. Here we report the effects
of norrin on protease-mediated death of RGC-5 cells.
METHODS
Materials: Dulbecco’s modified Eagle’s medium (DMEM),
Dulbecco’s phosphate buffered saline (DPBS), penicillin, and
streptomycin  were  obtained  from  Invitrogen  Corporation
(Carlsbad,  CA).  Staurosporine  was  obtained  from  Alexis
Biochemicals  (San  Diego,  CA).  Human  glu-plasminogen
(product #410) and human fibrinogen (product #431) were
obtained  from  American  Diagnostica  (Stamford,  CT).
Recombinant  Dkk1  was  obtained  from  R&D  systems
(Minneapolis,  MN)  and  3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium  bromide  (MTT)  was  obtained  from
Sigma Chemical Company (St. Louis, MO).
Cell  culture:  Transformed  RGC-5  cells  were  cultured  in
DMEM containing 1 g/l glucose, 10% fetal bovine serum
(FBS),  100  U/ml  penicillin,  and  100  μg/ml  streptomycin.
RGC-5 cells (from passage 10–20) were treated with 2.0 μM
staurosporine  to  induce  their  differentiation  as  described
previously [10,11]. Briefly, cells were cultured overnight in
DMEM containing FBS. The next morning, cells were washed
three times with phosphate buffered saline (PBS; 3.2 mM,
Na2HPO4, 0.5 mM KH2PO4, 1.3 mM KCl, 135 mM NaCl, pH
7.4) and incubated in serum-free medium supplemented with
2.0 μM staurosporine. Where indicated, cells were also treated
with SS+norrin, SS+Dkk1, and SS+H-89. Cells morphology
was observed by using an inverted, phase contrast, and bright-
field microscope, and digitized images were obtained by using
a Nikon D100 digital camera (Nikon Corporation, Tokyo,
Japan).
Cell viability: Cells plated at 4×103 cells/ml in 96 well tissue
culture plates were left untreated or treated for 48 h with
2.0 μM SS along with indicated concentrations of norrin,
Dkk1, and H-89 in serum-free DMEM. At 48 h after the
treatment, cell viability was determined by incubating cells
with 1.2 mM MTT for 2 h at 37 °C. At the end of 2 h, the
formazan product produced by viable cells was dissolved in
0.01 M HCl, and the optical density was read at 570 nm by
using an automated microplate reader (Bio-Tek Instruments,
Inc., Winooski, VT). Statistical significance was analyzed by
nonparametric  Newman-Keuls  analog  procedure  (GB  Stat
Software, Dynamic Microsystems, Silver Spring, MD).
Activation of Wnt pathway: Accumulation of beta-catenin in
the nucleus, an indicator for activation of Wnt pathway, was
measured by western blot analysis [12]. Briefly, RGC-5 cells
(2×106)  were  plated  in  100  mm  tissue  culture  plates  and
incubated overnight at 37 °C. Afterwards, cells were washed
three times with PBS and cells were either left untreated or
treated for 24 h with 25 ng/ml norrin, SS (2.0 μM), or SS
(2.0  μM)  and  norrin.  At  the  end  of  treatment,  cells  were
washed three times with PBS, scraped into 1 ml PBS, and
transferred  into  individual  Eppendorf  tubes.  Cells  were
centrifuged for 1 min at 16.1x g and the supernatants were
discarded. Cells were then resuspended in 0.4 ml lysis buffer,
composed of 10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM
EDTA, 0.1 mM EGTA, and 1 mM dithiothreitol, along with
protease inhibitors (complete mini protease inhibitor cocktail,
Roche Diagnostics). Cells were allowed to swell on ice for 20
min followed by the addition of 12.5 μl 10% Nonidet P-40.
The tubes containing cells were vortexed vigorously for 10 s,
and the homogenates were centrifuged at 16.1x g for 30 s.
Supernatants containing cytoplasmic proteins were collected
into  fresh  Eppendorf  tubes.  The  nuclear  pellets  were
resuspended  in  25  μl  ice-cold  nuclear  extraction  buffer,
composed of 20 mM HEPES, pH 7.9, 400 mM NaCl, 1 mM
EDTA,  1  mM  EGTA,  1  mM  dithiothreitol,  and  protease
inhibitors, then incubated on ice for 30 min with intermittent
vortexing. Samples were centrifuged for 5 min at 4 °C (16.1x
g),  and  the  supernatants  containing  nuclear  proteins  were
transferred into fresh Eppendorf tubes. Protein content was
measured  by  using  BCA  protein  assay  reagent  (Pierce,
Rockford, IL) and aliquots containing equal amount of nuclear
and cytoplasmic proteins (20 mg) were separated on 10%
SDS-polyacrylamide gels. After separation, the proteins were
transferred to polyvinylidene fluoride (PVDF) membranes
and incubated for 1 h in 10% nonfat dry milk prepared in Tris-
buffered saline containing 0.1% Tween-20 (TBS-T). PVDF
membranes  were  incubated  overnight  with  polyclonal
antibodies against beta-catenin (Cell Signaling Technology,
Danvers, MA). Membranes were washed with TBS-T and
incubated  for  1  h  at  room  temperature  with  appropriate
secondary antibodies conjugated to horseradish peroxidase
(HRP). Finally, the proteins were detected by using an ECL
chemiluminescence kit (Pierce, Rockford, IL). Equal loading
of nuclear and cytoplasmic proteins was determined by re-
probing  the  membranes  with  antibodies  against  TATA-
binding protein (Abcam, Boston, MA) and actin, respectively.
Relative level of beta-catenin was determined by using image
analysis software (Scion Corporation, Frederick, MD), and
the results were represented as mean arbitrary units. Statistical
significance was analyzed by nonparametric Newman-Keuls
analog  procedure  (GB  Stat  Software,  Dynamic
Microsystems).
Phosphorylation of LRP-1: RGC-5 cells (2×106 cells) plated
in 100 mm tissue culture plates were either left untreated or
were treated 24 h with 2.0 μM SS and indicated concentrations
of norrin and H-89. At the end of 24 h, cells were washed twice
with DPBS. Cells were scraped into 2 ml DPBS, transferred
into pre-cooled 15 ml centrifuge tubes, and centrifuged at
13.4x g for 10 min at 4 °C. The supernatant was discarded and
500 μl of RadioImmuno Precipitation Assay (RIPA) buffer
(1% nonidet-P40, 20 mM Tris-HCl, 150 mM NaCl, 1 mM
Na3VO4, pH 7.4) buffer was added to each tube, and the tubes
were incubated at 4 °C for 30 min on rotary shaker. Thirty min
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27after incubation, cells were centrifuged and supernatants were
collected into 1.5 ml Eppendorf tubes. Protein content was
estimated  by  using  Bio-Rad  protein  assay.  Aliquots
containing 500 μg total proteins from each treatment were
incubated overnight 4 °C with 2  μl polyclonal antibodies
against lipoprotein-related receptor-1 (LRP-1; Orbigen, San
Diego, CA). Next, 100 μl Protein G-Sepharose (Invitrogen
Corporation) was added to each sample, and samples were
incubated  at  4  °C  for  4  h.  Tubes  containing  Protein  G-
Sepharose were centrifuged for 2 min at 13.4x g and the
supernatant was discarded. SDS-loading buffer (25 μl) was
added to the pellet, and the tubes containing the pellet were
boiled for 5 min. Tubes were centrifuged again to remove
sepharose beads, and the supernatant was loaded onto 10%
SDS–PAGE  gels.  After  separation,  the  proteins  were
transferred to PVDF membranes and incubated for 1 h in 10%
nonfat dry milk prepared in TBS-T. PVDF membranes were
then probed with polyclonal antibodies against phosphoserine
(Cell Signaling), phosphotyrosine (clone 4G10; Millipore,
Billerica, MA), and 1:1,000 dilution LRP-1 (Orbigen). After
overnight  incubation  with  primary  antibodies,  membranes
were washed twice with TBS-T and incubated for 1 h at room
temperature  with  appropriate  secondary  antibodies
conjugated to HRP. Finally, the proteins on the membranes
were detected by using an enhanced chemiluminescence kit
(Pierce). Relative level of proteins was determined by using
Scion  image  analysis  software,  and  the  results  from  3
independent experiments were represented as mean arbitrary
units. Statistical significance was analyzed by non-parametric
Newman-Keuls  analog  procedure  (GB  Stat  Software,
Dynamic Microsystems).
Zymography: Proteolytic activity of tPA and uPA in RGC-5
cells  was  determined  by  plasminogen  and  fibrinogen
zymography assays as previously described [10,11]. Briefly,
aliquots containing 20 μl conditioned medium were mixed
with 4X SDS gel-loading buffer and loaded onto 10% SDS
polyacrylamide  gels  containing  5.5  mg/ml  fibrinogen  and
50 μg/ml plasminogen. After electrophoresis, the gels were
washed three times with 2.5% Triton-X 100 (15 min each
time)  to  remove  SDS  from  the  gels,  and  the  gels  were
incubated overnight in 0.1 M glycine-buffer (pH 8.0) at 37 °C.
After overnight incubation, the gels were stained with 0.2%
Coomassie brilliant blue-R250 for 5 min and then destained
with a solution containing 50% methanol and 10% acetic acid
in  deionized  water.  Proteolytic  activity  of  tPA  and  uPA,
evident as clear bands in the zymograms, was documented
using the Kodak EDAS 290 imaging system (Eastman Kodak
Company, Rochester, NY). Relative level of protease activity
was  determined  by  using  image  analysis  software  (Scion
Corporation), and the results from 3 independent experiments
were  represented  as  mean  arbitrary  units.  Statistical
significance was analyzed by non-parametric Newman-Keuls
analog  procedure  (GB  Stat  Software,  Dynamic
Microsystems).
RESULTS
Effect of norrin on expression of tPA and uPA, and on death
of RGC-5 cells: Throughout this study, RGC-5 cells were
treated with 2.0 μM staurosporine to investigate the effects of
norrin.  This  particular  concentration  was  chosen  because
RGC-5 cells synthesize elevated levels of tPA and uPA at this
concentration, and elevated levels of tPA and uPA, in turn,
cause death of RGC-5 cells [10,11]. Cells were left untreated
or treated for 48 h with varying concentrations of norrin alone,
SS (2.0 μM) alone, or SS (2.0 μM) and varying concentrations
of  norrin.  At  the  end  of  48  h,  conditioned  medium  was
collected  and  proteolytic  activity  of  tPA  and  uPA  was
determined by plasminogen/fibrinogen zymography assays.
Zymography assays indicated that RGC-5 cells secreted low
levels of uPA constitutively (Figure 1A). RGC-5 cells treated
with increasing doses of norrin also secreted low levels of uPA
similar to the levels secreted by untreated cells (Figure 1A,B)
and the levels were not significantly different from untreated
cells. In contrast, compared to untreated RGC-5 cells, cells
treated with SS alone or SS and norrin secreted elevated levels
of  both  uPA  and  tPA  (Figure  1C),  and  the  levels  were
significantly different from untreated cells (Figure 1C,D).
Comparison of proteolytic activity (Figure 1B,D) with cell
survival (Figure 1E,F) indicates that the survival of RGC-5
cells was significantly decreased under SS-treated conditions,
but not under combined SS- and norrin-treated conditions
despite the fact that RGC-5 cells synthesized similar levels of
tPA and uPA under both treatment conditions.
To investigate the time course effect of norrin on cell
survival, we treated RGC-5 cells for 24 and 48 h with 2.0 μM
SS with or without 25 ng/ml norrin. From this experiment
forward, we chose 25 ng/ml norrin to treat the cells because
norrin seems to elicit optimum effect on the expression of tPA
and uPA, and on cell survival at this concentration (see Figure
1F). At the end of the treatment period, levels of tPA and uPA,
and  cell  survival  were  investigated  as  described  in  the
previous  section.  Zymography  assays  indicated  that,
regardless of the presence of norrin, RGC-5 cells synthesized
similar levels of uPA at 24 h after treatment (Figure 2A,B)
and both tPA and uPA at 48 h after treatment (Figure 2D,E).
Cell viability assays indicated that low levels of uPA had no
effect on cell survival at 24 h after treatment (Figure 2C). In
contrast, increased levels of both tPA and uPA reduced the
survival of RGC-5 cells at 48 h after treatment (Figure 2F). In
addition, despite elevated levels of tPA and uPA, a significant
number of RGC-5 cells survived in the presence of norrin
(Figure 2F).
Effect of norrin on Wnt-pathway activation: To investigate
whether  Wnt  pathway  plays  a  role  in  norrin-mediated
protective  effect,  we  employed  western  blot  analysis  to
determine the translocation of beta-catenin into the nucleus.
Western blot analysis performed on nuclear extracts prepared
from RGC-5 cells indicated that a low level of beta-catenin
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28was constitutively present in nuclear proteins extracted from
cells  left  untreated  or  treated  with  norrin  (Figure  3A).  In
contrast, in the presence of norrin, a significant increase in
beta-catenin levels was observed in nuclear proteins extracted
from cells treated with norrin or both SS and norrin (Figure
3A,B)  indicating  that  norrin,  indeed,  activates  Wnt-beta-
catenin pathway. Comparison of nuclear translocation of beta-
catenin with cell viability (Figure 3C) indicated that increased
survival  of  RGC-5  cells  under  combined  norrin-  and  SS-
treated conditions associated with nuclear translocation of
beta-catenin.
Figure 1. Effect of norrin on tPA and
uPA  expression,  and  on  survival  of
RGC-5 cells. In the absence (A,B,E) or
presence of 2.0 μM staurosporine (SS;
C,D,F), RGC-5 cells were left untreated
or  treated  for  48  h  with  varying
concentrations  of  norrin  (n=3
experiments).  At  the  end  of  48  h,
conditioned medium was collected and
proteolytic  activity  of  tissue
plasminogen  activator  (tPA)  and  and
urokinase plasminogen activator (uPA)
was determined by zymography assays
(A,C),  relative  amount  of  proteolytic
activity  was  determined  by
densitometric analysis (B,D), and cell
viability  was  assessed  by  3-[4,5-
dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium  bromide  (MTT)
assays  (E,  F).  In  the  absence  of  SS,
norrin had no effect on low levels of
uPA expressed constitutively by RGC-5
cells  (A,B;  NS  is  not  significant).  In
addition, lower concentrations of norrin
had no effect on cell survival, but higher
concentrations of norrin (50 and 100 ng/
ml) increased cell survival significantly
(E, *p<0.05). Compared to low levels of
uPA expressed by untreated cells, uPA
(D,  #p<0.05)  and  tPA  (D,  **p<0.05)
levels were significantly increased in SS
alone or in SS and norrin-treated cells.
Nonetheless,  survival  of  RGC-5  cells
decreased significantly in the presence
of SS alone (F, *p<0.05), but not in the
presence  of  SS  and  norrin  (F,
**p<0.05).
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29To  determine  whether  inhibition  of  Wnt-beta-catenin
pathway reduces norrin's protective effect, RGC-5 cells were
left untreated or treated with norrin, Dkk1 (a potent inhibitor
for Wnt-beta-catenin pathway; 0.25-4.0 µg/ml) [13] or Dkk1
and norrin. In addition, cells were treated with either SS only,
SS and norrin, SS and Dkk1, or combined SS, norrin, and
Dkk1. Results presented in Figure 3D indicate that in the
absence of SS, Dkk1 had no effect on survival of RGC-5 cells
regardless of norrin’s presence. In contrast, in the presence of
SS, norrin enhanced survival of RGC-5 cells (Figure 3E),
consistent with results presented in Figure 1F. When cell
survival under combined SS- and norrin-treated conditions
was  compared  with  combined  SS-,  norrin-,  and  Dkk1-
treatment, although cell survival was reduced to a large extent
with Dkk1, cell survival was not reduced to a level observed
under SS alone-treated conditions (Figure 3E). These results
suggest that beta-catenin activation alone is insufficient to
account for norrin-mediated protective effect on RGC-5 cells.
Effect of norrin on phosphorylation of LRP-1: To investigate
the mechanisms (other than Wnt/beta-catenin pathway) by
which  norrin  attenuated  tPA  and  uPA-mediated  death  of
RGC-5 cells, we have focused our attention on LRP-1 because
tPA and uPA induces death of RGC-5 cells by interacting with
this cell surface receptor. First, we investigated whether norrin
downregulates the expression of LRP-1. Our western blot
studies indicated that RGC-5 cells left untreated or treated
with either SS only or combined SS and norrin expressed
similar levels of LRP-1 protein (data not shown). These results
indicate that downregulation of LRP-1 is not responsible for
norrin-mediated survival of RGC-5 cells.
Since recent studies indicated that phosphorylation status
of the cytoplasmic domain of LRP-1 plays a crucial role in
signal  transduction  [14-16],  we  have  hypothesized  that
phosphorylation  status  of  LRP-1  may  underlie  norrin-
mediated  survival  of  RGC-5  cells.  To  investigate  this
hypothesis, RGC-5 cells were left untreated or treated with
norrin alone, SS alone, or SS and norrin. At the end of the
Figure 2. Time course effect of norrin on
tPA and uPA expression, and on cell
survival.  RGC-5  cells  were  left
untreated or treated for 24 h and 48 h
with staurosporine (SS) only (2.0 μM),
norrin only (25 ng/ml), or SS and norrin
(n=3  experiments). At  the  end  of  the
treatment,  conditioned  medium  was
collected, proteolytic activity of tissue
plasminogen  activator  (tPA)  and
urokinase plasminogen activator (uPA)
was determined by zymography assays
(A,D),  and  relative  amount  of
proteolytic activity was determined by
densitometric  analysis  (B,E).  Cell
viability  was  determined  by  3-[4,5-
dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium  bromide  (MTT)
assays (C,F). Compared to low levels of
uPA  present  in  untreated  cells  or  in
norrin  alone-treated  cells  (A,B),  uPA
levels were increased in SS (B, *p<0.05)
or  in  SS  and  norrin-treated  cells  (B,
**p<0.05)  at  24  h  after  treatment.
However, increased levels of uPA alone
had no effect on cell survival (C, not
significant,  NS).  Compared  to  low
levels of uPA present in untreated cells
or in norrin alone-treated cells (D,E),
uPA (E, *p<.0.05, **p<0.05) and tPA
(E, %p<0.05, %%p<0.05) levels were
increased significantly in SS or in SS
and  norrin-treated  cells  at  48  h  after
treatment.  Nonetheless,  survival  of
RGC-5  cells  decreased  in  SS  alone-
treated cells (F, *p<0.05) but not in SS
and norrin-treated cells (F,**p<0.05).
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30treatment, proteins were extracted and immunoprecipitated by
using antibodies against LRP-1. Immunoprecipitated protein
complexes were then subjected to western blot analysis by
using antibodies against pSer and pTyr residues. Western blot
analysis indicated constitutive phosphorylation of LRP-1 at
both Ser and Tyr-residues in cells left untreated or treated with
norrin (Figure 4A,B). When cells were treated with SS, LRP-1
phosphorylation was reduced at Ser-residues, but not at Tyr-
residues (Figure 4A,B). In contrast, Ser-phosphorylation of
LRP-1, reduced by SS, was increased largely when cells were
treated  with  SS  and  norrin  (Figure  4A,B).  These  results
indicate that norrin attenuates the effect of SS, in part, by
Figure 3. Effect of norrin on Wnt-beta-
catenin  pathway  activation.  Retinal
ganglion cell (RGC)-5 cells were left
untreated or treated for 24 h with 2.0
μM staurosporine (SS) only or 25 ng/ml
SS and norrin. At the end of 24 h, cells
were  photographed  (C),  cytoplasmic
and nuclear proteins were prepared (n=3
experiments),  and  aliquots  containing
equal amount of protein (20 μg) were
subjected  to  western  blot  analysis  by
using  antibodies  against  beta-catenin
(A).  Equal  loading  of  nuclear  and
cytoplasmic proteins was determined by
reprobing  the  membranes  with
antibodies  against  TATA  binding
protein  (TBP)  and  actin,  respectively
(A). Compared to untreated cells, beta-
catenin levels in nuclear fractions were
increased significantly in norrin-treated
cells  (A,B,  *p<0.05)  and  in  SS  and
norrin-treated  cells  (A,B,**p<0.05).
Micrographs of cells (C) indicate that
elevated  levels  of  beta-catenin
associated with increased cell survival.
To determine whether inhibition of Wnt
pathway  reduces  norrin-mediated  cell
survival,  cells  were  left  untreated  or
treated for 48 h with norrin (25 ng/ml),
Dkk1  (0.25–4.0  μg/ml),  or  Dkk1  and
norrin, in the absence (D) or presence of
2  μM  SS  (E)  and  cell  viability  was
assessed  by  3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyltetrazolium  bromide
(MTT) assays (n=3 experiments). In the
absence SS, Dkk1 had no effect on cell
survival regardless of the presence of
norrin  (D,  NS  is  not  significant).
Compared to SS-treated cells, survival
of SS and norrin-treated cells increased
significantly  (E,*p<0.05).  Although
Dkk1  reduced  norrin-mediated  cell
survival of RGC-5 cells (E, %p<0.05),
Dkk1  failed  to  reduce  the  survival
similar to that observed under SS alone-
treated conditions.
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31Figure 4. Effect of norrin on LRP-1 phosphorylation. Retinal ganglion cell (RGC)-5 cells were left untreated or treated for 24 h with 2.0 μM
staurosporine (SS) alone or SS and 25 ng/ml norrin (n=2 experiments). At the end of 24 h, cells were collected, proteins were extracted, and
immunoprecipitated by using antibodies against lipoprotein-related receptor-1 (LRP-1). Immunoprecipitated proteins were subjected to
western blot analysis by using antibodies against anti-phosphoserine, anti-phosphotyrosine, and anti-LRP-1 (A). Relative levels of proteins
were determined by densitometry (C). At the end of treatment, conditioned medium was collected, and proteolytic activity of tissue
plasminogen activator (tPA) and urokinase plasminogen activator (uPA) was determined by zymography assays (B). Relative amount of
proteolytic activity was determined by densitomety (D). LRP-1 was expressed constitutively in untreated cells and its expression did not
change  regardless  of  the  treatment  condition  (A).  LRP-1  was  phosphorylated  at  Tyr-residues  constitutively  in  untreated  cells  and
phosphorylation status of LRP-1 at Tyr-residuces was not altered with any of the treatment conditions (A). LPR-1 was constitutively
phosphorylated at Ser-residues in untreated cells (A). Norrin-treatment alone had no effect on LPR-1 phosphorylation at Ser-residues, but SS-
treatment significantly reduced Ser-phosphorylation of LRP-1 (A, C, *p<0.05). Nonetheless, LPR-1 phosphorylation at Ser-residues was
significantly increased in the presence of SS and norrin (A,C, **p<0.05). RGC-5 cells were left untreated or treated for 48 h with 2.0 μM SS
and 25 ng/ml norrin in serum-free medium (n=3 experiments). Compared to low levels of uPA in untreated cells, levels of both uPA (B,D,
*p<0.05) and tPA (B,D, %p<0.05) were increased in the presence of SS. In addition, compared to low levels of uPA in norrin-treated cells,
levels of both uPA (B,D, **p<0.05) and tPA (B,D, %%p<0.05) were significantly increased in the presence of SS and norrin. Nonetheless,
cell viability assays (E) indicate that survival of RGC-5 cells decreased significantly under SS-treated conditions (E,*p<0.05), but not under
SS and norrin-treated conditions (E, **p<0.05). NS, not significant.
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32Figure 5. Effect of protein kinase inhibitors on phosphorylation of LRP-1. Retinal ganglion cell (RGC)-5 cells were left untreated or treated
for 24 h with staurosporine (SS; 2.0 μM), norrin (25 ng/ml), with or without H-89 (n=3 experiments). At the end of 24 h, proteins were extracted
and immunoprecipitated by using antibodies against lipoprotein-related receptor-1 (LRP-1). Immunoprecipitated proteins were then subjected
to western blot analysis by using antibodies against phosphoserine, phosphotyrosine, and LRP-1 (A). Relative amount of proteins was
determined by densitometric analysis (B). LRP-1 was expressed constitutively in norrin-treated cells and its expression did not change
regardless of treatment condition (A). LRP-1 was phosphorylated at Tyr-residues constitutively in norrin-treated cells and phosphorylation
status of LRP-1 at Tyr-residues did not change with any of the treatment condition (A). In addition, LPR-1 was constitutively phosphorylated
at Ser-residues in norrin-treated cells (A). Compared to Ser-phosphorylation of LRP-1 in norrin-treated cells, Ser-phosphorylation of LRP-1
was significantly reduced when cells were treated with H-89 (A, B, *p<0.05). In addition, compared to Ser-phosphorylation of LRP-1 under
SS and norrin-treated conditions, Ser-phosphorylation of LRP-1 was further reduced under H-89, SS, and norrin-treated conditions (A,B,
**p<0.05). Cell viability assays indicate that, in the absence of SS, lower concentrations of H-89 had no effect on cell survival, but higher
concentrations of H-89 (2.5–10.0 μM) decreased cell survival significantly regardless of norrin's presence (C, *p<0.05). Furthermore, in the
presence of SS, lower concentrations of H-89 had no effect on cell survival, but higher concentrations of H-89 (2.5–10.0 μM) decreased norrin-
mediated cell survival (D, *p<0.05).
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33regulating  the  phosphorylation  of  LRP-1.  Comparison  of
phosphorylation of LRP-1 with tPA and uPA levels (Figure
4C,D) indicated that the phosphorylation status of LRP-1 does
not affect the levels of tPA and uPA. However, comparison
of phosphorylation of LRP-1 (Figure 4A) with MTT assays
(Figure 4E) indicated that phosphorylation status of LRP-1
affected the survival of RGC-5 cells. Results presented in
Figure 4 show that despite elevated levels of tPA and uPA
(Figure 4C,D), a significant number of RGC-5 cells survived
(Figure 4E) as long as LRP-1 was phosphorylated at both Ser
and Tyr-residues (Figure 4A).
To  identify  the  kinases  responsible  for  LRP-1
phosphorylation, we have concentrated our efforts on protein
kinase A (PKA) and protein kinase C (PKC) because these
kinases have been shown to regulate the phosphorylation of
LRP-1.  Since  SS  (inhibitor  for  PKCs)  reduced  the
phosphorylation of LRP-1 at Ser-residues in RGC-5 cells (see
Figure 4A), we have ruled out the role of PKCs in LRP-1
phosphorylation under SS and norrin-treated conditions. To
investigate  whether  PKA  plays  a  role  in  norrin-mediated
phosphorylation of LRP-1, RGC-5 cells were left untreated or
treated with 5 μM H-89 (a PKA inhibitor) [16], norrin alone,
or combined norrin and 5 μM H-89. In addition, RGC-5 cells
were treated with SS only, SS and H-89, SS and norrin, or
combined  SS,  norrin,  and  H-89.  After  the  treatment,
phosphorylation  of  LRP-1  was  assessed  by  western  blot
analysis as described in the previous section. Western blot
analysis indicated that LRP-1 was phosphorylated at Ser- and
Tyr-residues when treated with norrin alone or norrin plus SS
(Figure 5A,B), consistent with the results presented in Figure
4A. When LRP-1 phosphorylation was compared between
norrin  only  or  norrin  and  H-89-treated  cells,  Ser-
phosphorylation of LRP-1 was reduced by about 15%–20%.
In the presence of SS and norrin, H-89 led to an additional
reduction in LRP-1 phosphorylation, suggesting that PKA
plays a role in norrin-mediated phosphorylation of LRP-1.
Finally, to investigate the role of PKA on survival of
RGC-5 cells, cells were left untreated or treated with 0.625–
10 μM H-89 only, norrin only, or combined norrin and 0.625–
10 μM H-89, with or without SS. At the end of the treatment
cell viability was determined by MTT assays (Figure 5C,D).
Results presented in Figure 5C indicate that 2.5−10 μM H-89
alone,  in  the  presence  or  absence  of  norrin,  significantly
reduced the viability of RGC-5 cells, indicating that PKA, in
part, plays a role in survival of RGC-5 cells under normal
conditions. In addition, when survival of RGC-5 cells was
compared  between  SS-  and  norrin-treated  conditions,  and
combined SS-, norrin-, and H-89-treated conditions (Figure
5D), cell survival was further reduced under 2.5–10 μM H-89-
treated conditions. These results indicate that PKA, in part,
plays a role in norrin-mediated survival of RGC-5 cells.
DISCUSSION
Recent  studies  indicated  that  norrin,  which  regulates  the
regression of hyaloid vessels in the retina [3,6,7,17,18] and
acts as a nonconventional ligand for Wnt pathway, prevents
loss of RGCs in norrin-deficient Ndpy/- mice [6]. Yet, it is
unclear how norrin attenuates loss of RGCs.
In this study, we have used transformed RGC-5 cells as
an in vitro model system to investigate the effects of norrin on
cell death. We have chosen RGC-5 cells because they express
markers such as Thy-1, Brn-3c, and neuritin characteristic of
primary RGCs, and have extensively been used as an in vitro
model  system  to  investigate  the  effect  of  oxidative  stress
[19], sigma-1 receptor ligands [20], thioredoxins [21], visible
light  exposure  [22],  and  hydrostatic  pressure  [23,24].
Although RGC-5 cells have been widely used, they differ
from  primary  RGCs  in  many  respects  including  their
proliferative nature and resemblance to glial cells in culture.
Studies by Frassetto et al. [25] have reported that RGC-5 cells
can be differentiated into neuronal-like cells by treating them
with  SS,  a  broad-spectrum  protein  kinase  inhibitor.  By
employing RGC-5 cells and by treating them with SS, we have
previously reported that SS induces tPA and uPA expression
in RGC-5 cells, and elevated levels of these proteases directly
cause the death of RGC-5 cells by interacting with LRP-1
[10,11]. Therefore, we have used RGC-5 cells to investigate
the effect of norrin on tPA and uPA-mediated cell death, and
made several important observations: 1) norrin attenuated SS-
mediated death of RGC-5 cells, without altering the levels of
tPA and uPA; 2) norrin-mediated survival of RGC-5 cells was
associated with activation of Wnt/beta-catenin pathway, but
inhibition of Wnt pathway did not reduce norrin-mediated
survival of RGC-5 cells completely; and 3) norrin attenuated
tPA and uPA-mediated death of RGC-5 cells, in part, by
regulating the phosphorylation status of LRP-1, a cell surface
receptor for both tPA and uPA.
Based on the results presented in this study, we propose
that  both  PKA  and  PKC  contribute  to  constitutive
phosphorylation of LRP-1 in undifferentiated RGC-5 cells
(Figure 6). Under these conditions, low levels of uPA do not
cause death of RGC-5 cells because LRP-1 is phosphorylated
constitutively. Since SS is a PKC inhibitor, we propose that
SS reduces PKC levels in differentiated cells, and the reduced
PKC fails to phosphorylate LRP-1. We believe that under
these conditions, elevated levels of tPA and uPA cause death
of RGC-5 cells because LRP-1 is not phosphorylated at Ser-
residues. On the other hand, with addition of norrin, LRP-1
remains phosphorylated at the Ser-residues, and under these
conditions, survival of RGC-5 cells increases despite elevated
levels of tPA and uPA. We propose that Wnt pathway alone
is not responsible for the norrin-mediated protective effect
since  inhibition  of  Wnt  pathway  did  not  decrease  norrin-
mediated protection completely. Since norrin restored LRP-1
phosphorylation and attenuated cell death despite elevated
levels of tPA and uPA, and since norrin-mediated protection
was reduced by the PKA inhibitor, we propose that norrin
restores phosphorylation of LRP-1, in part, by regulating PKA
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34levels in RGC-5 cells. Finally, we propose that as long as
LRP-1 is phosphorylated, elevated levels of tPA and uPA do
not cause death of RGC-5 cells.
It is interesting to speculate the mechanisms underlying
phosphorylation  of  LRP-1  and  survival  of  RGC-5  cells.
Although a growing body of evidence indicates that LRP-1
plays  a  role  in  the  pathophysiology  of  cerebral  ischemia
[26-29] and deletion of LRP-1 in mouse is embryonic lethal
[30], two important aspects of LRP-1 are still unclear. First,
how  does  LRP-1  regulates  cell  survival?  Second,  does
phosphorylation status of LRP-1 receptor plays a role in cell
survival? Since the cytoplasmic domain of LRP-1 contains
NPXY motifs that bind to a variety of adaptor proteins, it has
been  speculated  that  LRP-1  controls  a  variety  of  cells
functions including cell survival [31]. For example, previous
studies have suggested that LRP-1 may regulate cell survival
by activating the PI3-Akt pathway [32,33], by preventing
nuclear translocation of activated c-Jun N-terminal protein
kinase (JNK) to the nucleus [34] or by controlling activation
of caspases [32]. In addition, several previous studies have
used the receptor-associated protein (RAP), a LRP-1 receptor
antagonist, and reported that LRP-1 regulates several cellular
functions  [35-38].  Furthermore,  studies  from  our  own
laboratory  have  reported  that  RAP  inhibits  tPA  and  uPA
interaction with LRP-1, and attenuates tPA and uPA-mediated
death  of  RGC-5  cells  [11].  However,  the  link  between
phosphorylation status of LRP-1 and cell death has not been
reported. To our knowledge, this is the first report describing
the link between phosphorylation of LRP-1 and cell death, at
least in transformed RGC-5 cells.
The  precise  mechanisms  by  which  norrin  affects  the
phosphorylation of LRP-1 are currently unclear. It is plausible
that norrin may regulate certain kinases and the kinases, in
Figure 6. Proposed model for norrin’s role on RGC-5 cells. Our
working hypothesis is that under normal conditions, phosphorylated
LRP-1 receptor prevents uPA-mediated cell death. SS, by inhibiting
PKC, downregulates LRP-1 phosphorylation, and in the absence of
LRP-1 phosphorylation, elevated levels of tPA and uPA cause death
of RGC-5 cells. In contrast, norrin prevents tPA and uPA-mediated
cell death, in part, by restoring phosphorylation of LRP-1 and, in part,
by activating Wnt pathway.
turn, may alter the phosphorylation of LRP-1. In this context,
previous studies have shown that the signaling functions of
LRP-1  are  mediated  through  phosphorylation  of  its
cytoplasmic domain [4,39]. For example, PKA plays a role in
Ser-phosphorylation  [14],  while  platelet-derived  growth
factor  (PDGF)  induces  phosphorylation  of  Tyr  in  the
cytoplasmic domain of LRP-1 [15]. In our study, we have
shown  that  norrin  regulates  phosphorylation  of  LRP-1
through PKA. An additional possibility is that certain genes
activated  by  Wnt  pathway  may,  in  turn,  regulate  norrin-
mediated protective effect in RGC-5 cells. Finally, LRP-1 can
alter the Wnt pathway by disrupting LRP5/6 and Frizzled
complexes [40].
There are few caveats associated with study. First, the
current study used transformed RGC-5 cells for investigating
the effect of norrin. Therefore, the results presented in this
study are applicable only to cultured RGC-5 cells, and not
applicable to primary RGCs. Second, since the current used
SS  (a  PKC  inhibitor)  to  differentiate  RGC-5  cells  and  to
induce death of RGC-5 cells, the relevance of these results to
a clinical situation is a concern. Yet, based on recent studies
that used SS to induce death of RGCs in animal models, we
believe that these results will also be applicable to clinical
situations. For example, Cordeiro et al. [41] have injected SS
into the vitreous humor of dark Agouti rats and macaque
monkeys to induce apoptosis of RGCs, and reported that this
model  system  is  useful  to  investigate  the  mechanisms
underlying retinal neuro-degenerative diseases. Furthermore,
recent  studies  indicate  that  the  SS-induced  model  system
represents as a glaucoma-related animal model to investigate
the role of glutamate receptors in RGCs’ death [42]. Future
studies aimed at understanding the effect of norrin in animal
models  of  SS-induced  cell  death  would  provide  a  better
understanding  of  the  mechanisms  underlying  norrin  in
survival of RGCs.
In  summary,  we  have  provided  evidence  that  norrin
attenuates tPA and uPA-mediated death of RGC-5 cells by
activating Wnt/beta-catenin pathway and by regulating the
phosphorylation of LRP-1, a cell surface receptor for both tPA
and uPA.
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